Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is reporting strong financial performance for FY26, with a positive revenue outlook driven by increasing prevalence of sleep apnea and ResMed's focus on digital health. However, some concerns remain regarding the competitiveness of European/ROW markets and the company's opex despite high revenue growth. Overall, despite a potentially competitive market and ongoing investments, ResMed's strong performance and focus on innovation make it a promising stock for the future.

Bears say

ResMed is showing strong top-line growth and solid improvements in gross margin and operating margin, indicating good operational performance. However, we are maintaining a neutral outlook due to potential headwinds from competition, regulatory changes, and the impact of the COVID-19 pandemic on the healthcare industry. Additionally, the company's ambitious investment in digital health may result in increased expenses and risks.

ResMed (RMD) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 10 analysts, ResMed (RMD) has a Buy consensus rating as of Apr 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $295.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $295.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.